GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (NAS:GMAB) » Definitions » Accounts Payable & Accrued Expense for Financial Companies

GMAB (Genmab AS) Accounts Payable & Accrued Expense for Financial Companies


View and export this data going back to 2010. Start your Free Trial

What is Genmab AS Accounts Payable & Accrued Expense for Financial Companies?

Accounts Payable & Accrued Expense for Financial Companies only applies to insurance companies.


Genmab AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (NAS:GMAB) » Definitions » Accounts Payable & Accrued Expense for Financial Companies
Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.